According to years of biochemical research, a broad-spectrum ANTI-VENOM compound inhibits the very enzyme that is associated with severe covid-19 disease and covid-19 mortality. It turns out that this enzyme (sPLA2) is inhibited by an anti-venom compound called varespladib. Clinical trials show that varespladib is a potent inhibitor of secretory phospholipase A2 (sPLA2). Varespladib has demonstrated improvements in cardiovascular risks, including a reduction in inflammatory C-reactive proteins and a near complete suppression of the target enzyme, sPLA2.
a Medscape article from 2020 concurred that the lung inflammation caused by covid-19 produces the sPLA2 enzyme. The article also said a more deadly version of the same enzyme is produced by SNAKE VENOM. Researchers are using varespladib as a broad-spectrum, anti-venom drug because it targets this same sPLA2 enzyme. Researchers also want to deploy the anti-venom compound against severe covid-19 cases.
This brings up the question: Could the clinical manifestation of “covid-19” actually be the ill effects of a bioweapon that contains properties from snake venom?The very enzyme that is associated with increased covid-19 mortality is blocked by an ANTI-VENOM compound – National Addiction News